Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04377711 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
A Phase 3 study of COVID-19, sponsored by Covis Pharma S.à.r.l..
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT04377711: Completed Phase 3 study of COVID-19, sponsored by Covis Pharma S.à.r.l..
NCT04377711 is a Phase 3 study of COVID-19 that has completed, run by Covis Pharma S.à.r.l.. The registered enrollment target is 400 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04377711, a Phase 3 study of COVID-19, has completed, sponsored by Covis Pharma S.à.r.l..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study
Primary Outcome
Time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, feeling feverish, repeated shaking with chills, muscle pain, headache, sore throat, and new loss of taste or smell, defined as symptom-free for a continuous period of more than 24 hours (ie, later than 3 AM/PM assessments) by day 30
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ciclesonide
Study Locations (1)
New York
- University of Buffalo - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2020-06-08 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 3 |
What the finished NCT04377711 record still lists
NCT04377711 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04377711 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04377711 about?
NCT04377711 is a clinical study titled "A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients". The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study
What is the current status of trial NCT04377711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2020-06-08. Estimated completion is 2021-01-05.
What conditions does trial NCT04377711 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04377711?
The interventions under investigation include: Placebo (DRUG), Ciclesonide (DRUG).
Who is sponsoring clinical trial NCT04377711?
This trial is sponsored by Covis Pharma S.à.r.l., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04377711 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04377711's enrollment target sits among peer trials
400 123rd of 298 higher than 175 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI